JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1997; 30:343-349
© 1997 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shapiro, S.
Right arrow Articles by Brundage, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shapiro, S.
Right arrow Articles by Brundage, B.

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

SM Shapiro, RJ Oudiz, T Cao, MA Romano, XJ Beckmann, D Georgiou, S Mandayam, LE Ginzton, and BH Brundage

Harbor-UCLA Medical Center, Saint John's Cardiovascular Research Center, Torrance 90509, USA.

OBJECTIVES: This study sought to determine the long-term effects of continuous infusion of epoprostenol (epo) therapy on survival and pulmonary artery pressure in patients with primary pulmonary hypertension (PPH). BACKGROUND: PPH is a progressive disease for which there are few effective therapies. METHODS: Patients with PPH and New York Heart Association functional class III or IV symptoms of congestive heart failure underwent right heart catheterization and Doppler-echocardiography to measure the maximal systolic pressure gradient between the right ventricle and right atrium (delta P) and cardiac output (CO). Doppler-echocardiography and catheterization data were compared. Patients were followed up long term with Doppler-echocardiography. RESULTS: Of 69 patients who went on to receive epo, 18 were followed up for > 330 days (range 330 to 700). During long-term follow-up, there was a significant reduction in delta P, which decreased from 84.1 +/- 24.1 to 62.7 +/- 18.2 (mean +/- SD, p < 0.01). A Kaplan-Meier plot of survival of our study patients demonstrated improved survival compared with that of historical control subjects. The 1-, 2- and 3-year survival rates for our patients were 80% (n = 36), 76% (n = 22) and 49% (n = 6) compared with 10- (88%, n = 31), 20- (56%, n = 27) and 30-month (47%, n = 17) survival rates in historical control subjects. CONCLUSIONS: Patients receiving continuous infusion of epo for treatment of PPH experience a decrease in pulmonary artery pressure. Long-term follow-up of this single-center patient group demonstrated improved long-term survival during epo therapy compared with that in historical control subjects and confirms predicted improved outcomes based on shorter follow-up periods.


This article has been cited by other articles:


Home page
 Therapeutic Advances in Respiratory DiseaseHome page
K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert
Review: Therapeutic advances in pulmonary arterial hypertension
Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265.
[Abstract] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
S. Takaoka, J. L. Faul, and R. Doyle
Current Therapies for Pulmonary Arterial Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148.
[Abstract] [PDF]

Home page
 HeartHome page
A. E Lammers, A. A Hislop, Y. Flynn, and S. G Haworth
Epoprostenol treatment in children with severe pulmonary hypertension
Heart, June 1, 2007; 93(6): 739 - 743.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
T. Handa, S. Nagai, S. Miki, Y. Fushimi, K. Ohta, M. Mishima, and T. Izumi
Incidence of Pulmonary Hypertension and Its Clinical Relevance in Patients With Sarcoidosis
Chest, May 1, 2006; 129(5): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. J. Rubin and D. B. Badesch
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Ann Intern Med, August 16, 2005; 143(4): 282 - 292.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H.-J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, and J. Winkler
Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy
Chest, August 1, 2005; 128(2): 709 - 713.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. Nagaoka, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki, H. Shimokawa, I. F. McMurtry, and M. Oka
Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 494 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Humbert, R.J. Barst, I.M. Robbins, R.N. Channick, N. Galie, A. Boonstra, L.J. Rubin, E.M. Horn, A. Manes, and G. Simonneau
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Eur. Respir. J., September 1, 2004; 24(3): 353 - 359.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Yung, A. C. Widlitz, E. B. Rosenzweig, D. Kerstein, G. Maislin, and R. J. Barst
Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension
Circulation, August 10, 2004; 110(6): 660 - 665.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. J. Oudiz, A. Widlitz, X. J. Beckmann, D. Camanga, J. Alfie, B. H. Brundage, and R. J. Barst
Micrococcus-Associated Central Venous Catheter Infection in Patients With Pulmonary Arterial Hypertension
Chest, July 1, 2004; 126(1): 90 - 94.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. McGoon, D. Gutterman, V. Steen, R. Barst, D. C. McCrory, T. A. Fortin, and J. E. Loyd
Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 14S - 34S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 35S - 62S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
V. V. McLaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. McCrory, T. Fortin, and G. Ahearn
Prognosis of Pulmonary Arterial Hypertension*: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 78S - 92S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst
Prostanoid therapy for pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Bresser, P.F. Fedullo, W.R. Auger, R.N. Channick, I.M. Robbins, K.M. Kerr, S.W. Jamieson, and L.J. Rubin
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
Eur. Respir. J., April 1, 2004; 23(4): 595 - 600.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S C Apostolopoulou, S Rammos, Z S Kyriakides, D J Webb, N R Johnston, D V Cokkinos, and D T. Kremastinos
Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease
Heart, October 1, 2003; 89(10): 1221 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. W Kenyon and J. M Nappi
Bosentan for the Treatment of Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. J. Barst, M. McGoon, V. McLaughlin, V. Tapson, R. Oudiz, S. Shapiro, I. M. Robbins, R. Channick, D. Badesch, B. K. Rayburn, et al.
Beraprost therapy for pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2119 - 2125.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. N. Kao and J. L. Faul
Emerging therapies for pulmonary hypertension: Striving for efficacy and safety
J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2126 - 2129.
[Full Text] [PDF]

Home page
 ChestHome page
F. Ono, N. Nagaya, H. Okumura, Y. Shimizu, S. Kyotani, N. Nakanishi, and K. Miyatake
Effect of Orally Active Prostacyclin Analogue on Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension Without Major Vessel Obstruction
Chest, May 1, 2003; 123(5): 1583 - 1588.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
J Rodes-Cabau, E Domingo, A Roman, J Majo, B Lara, F Padilla, I Anivarro, J Angel, J C Tardif, and J Soler-Soler
Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension
Heart, March 1, 2003; 89(3): 311 - 315.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. P. Kuhn, D. W. Byrne, P. G. Arbogast, T. P. Doyle, J. E. Loyd, and I. M. Robbins
Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving Epoprostenol
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 580 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Widlitz and R.J. Barst
Pulmonary arterial hypertension in children
Eur. Respir. J., January 1, 2003; 21(1): 155 - 176.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Raychaudhuri, A. Malur, T. L. Bonfield, S. Abraham, R. J. Schilz, C. F. Farver, M. S. Kavuru, A. C. Arroliga, and M. J. Thomassen
The Prostacyclin Analogue Treprostinil Blocks NFkappa B Nuclear Translocation in Human Alveolar Macrophages
J. Biol. Chem., August 30, 2002; 277(36): 33344 - 33348.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
O. Sitbon, M. Humbert, H. Nunes, F. Parent, G. Garcia, P. Herve, M. Rainisio, and G.e. Simonneau
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival
J. Am. Coll. Cardiol., August 21, 2002; 40(4): 780 - 788.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M.M. Hoeper, E. Spiekerkoetter, V. Westerkamp, R. Gatzke, and H. Fabel
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Eur. Respir. J., August 1, 2002; 20(2): 339 - 343.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, and I. Yamaguchi
A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats
J. Am. Coll. Cardiol., July 3, 2002; 40(1): 175 - 181.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J.-L. Vachiery, N. Hill, D. Zwicke, R. Barst, S. Blackburn, and R. Naeije
Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension*
Chest, May 1, 2002; 121(5): 1561 - 1565.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin
New Treatments for Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1209 - 1216.
[Full Text] [PDF]

Home page
 HeartHome page
C D Vizza, S Sciomer, S Morelli, C Lavalle, P Di Marzio, D Padovani, R Badagliacca, A R Vestri, R Naeije, and F Fedele
Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue
Heart, December 1, 2001; 86(6): 661 - 665.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
G. K. Lam, R. E. Stafford, J. Thorp, K. J. Moise Jr, and B. A. Cairns
Inhaled Nitric Oxide for Primary Pulmonary Hypertension in Pregnancy
Obstet. Gynecol., November 1, 2001; 98(5): 895 - 898.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
British Cardiac Society Guidelines and Medical Pra
Recommendations on the management of pulmonary hypertension in clinical practice
Heart, September 1, 2001; 86(90001): i1 - 13.
[Full Text] [PDF]

Home page
 ChestHome page
L. Appelbaum, M. Yigla, D. Bendayan, N. Reichart, G. Fink, I. Priel, Y. Schwartz, P. Richman, E. Picard, S. Goldman, et al.
Primary Pulmonary Hypertension In Israel : A National Survey
Chest, June 1, 2001; 119(6): 1801 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Ting, X.-G. Sun, M.-L. Chuang, D. A. Lewis, J. E. Hansen, and K. Wasserman
A Noninvasive Assessment of Pulmonary Perfusion Abnormality in Patients With Primary Pulmonary Hypertension
Chest, March 1, 2001; 119(3): 824 - 832.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
N. Galie
Do we need controlled clinical trials in pulmonary arterial hypertension?
Eur. Respir. J., January 1, 2001; 17(1): 1 - 3.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. V. AGUILAR and H. W. FARBER
Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1846 - 1850.
[Abstract] [Full Text]

Home page
 NEJMHome page
M. M. Hoeper, M. Schwarze, S. Ehlerding, A. Adler-Schuermeyer, E. Spiekerkoetter, J. Niedermeyer, M. Hamm, and H. Fabel
Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
N. Engl. J. Med., June 22, 2000; 342(25): 1866 - 1870.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
R Ziesche, V Petkov, K Wittmann, J Kopatschka, L Stiebellehner, P Schenk, P Germann, G Röder, R Ullrich, and L H Block
Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension
Heart, April 1, 2000; 83(4): 406 - 409.
[Abstract] [Full Text]

Home page
 ANN INTERN MEDHome page
D. B. Badesch, V. F. Tapson, M. D. McGoon, B. H. Brundage, L. J. Rubin, F. M. Wigley, S. Rich, R. J. Barst, P. S. Barrett, K. M. Kral, et al.
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease: A Randomized, Controlled Trial
Ann Intern Med, March 21, 2000; 132(6): 425 - 434.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R J BARST
Role of atrial septostomy in the treatment of pulmonary vascular disease
Thorax, February 1, 2000; 55(2): 95 - 96.
[Full Text]

Home page
 J Am Coll CardiolHome page
M. M. Hoeper, H. Olschewski, H. A. Ghofrani, H. Wilkens, J. Winkler, M. M. Borst, J. Niedermeyer, H. Fabel, W. Seeger, and the German PPH Study Group
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
J. Am. Coll. Cardiol., January 1, 2000; 35(1): 176 - 182.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. M. Robbins, S. P. Gaine, R. Schilz, V. F. Tapson, L. J. Rubin, and J. E. Loyd
Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus*
Chest, January 1, 2000; 117(1): 14 - 18.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Rich and V. V. McLaughlin
The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1184 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. Nagaya, M. Uematsu, Y. Okano, T. Satoh, S. Kyotani, F. Sakamaki, N. Nakanishi, K. Miyatake, and T. Kunieda
Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1188 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Aranda, K. K. Bradford, and R. G. Pearl
Combined Therapy with Inhaled Nitric Oxide and Intravenous Vasodilators During Acute and Chronic Experimental Pulmonary Hypertension
Anesth. Analg., July 1, 1999; 89(1): 152 - 152.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Langleben, R. J. Barst, D. Badesch, B. M. Groves, V. F. Tapson, S. Murali, R. C. Bourge, N. Ettinger, E. Shalit, L. M. Clayton, et al.
Continuous Infusion of Epoprostenol Improves the Net Balance Between Pulmonary Endothelin-1 Clearance and Release in Primary Pulmonary Hypertension
Circulation, June 29, 1999; 99(25): 3266 - 3271.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. B. Rosenzweig, D. Kerstein, and R. J Barst
Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects
Circulation, April 13, 1999; 99(14): 1858 - 1865.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. J. Barst, G. Maislin, and A. P. Fishman
Vasodilator Therapy for Primary Pulmonary Hypertension in Children
Circulation, March 9, 1999; 99(9): 1197 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
V. V. McLaughlin, D. E. Genthner, M. M. Panella, and S. Rich
Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension
N. Engl. J. Med., January 29, 1998; 338(5): 273 - 277.
[Abstract] [Full Text] [PDF]

Home page
 JWatch GeneralHome page
PROSTACYCLIN ANALOGUE THERAPY FOR PRIMARY PULMONARY HYPERTENSION
Journal Watch (General), August 19, 1997; 1997(819): 2 - 2.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1997 by the American College of Cardiology Foundation.